KW-6356: Research, Dosing, and Where to Buy in 2026
A research-first profile for KW-6356 (KW6356, KW 5356), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
KW-6356 is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 6 PubMed-cited papers, 8 attributed expert mentions, and 4 transcript dosing protocols for KW-6356, each linked to its source.
- Also indexed as KW6356, KW 5356.
- 4 aggregated dosing-protocol mentions from source transcripts.
- 6 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is KW-6356?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 4 cited mentions
"It's an adenosine blocker similar to caffeine but it's a little bit more selective and it's longlasting. So if you take that in the morning instead of having to dose coffee multiple times per day, you take this in the morning at 1 milligram 1.25 milligrams and that blocks the adenosine receptors all day long."
"The problem with KW-6356 is that it is 18-hour half-life. So for the people who are kind of sensitive to stimulants and don't really work hard, train hard, poor sleep hygiene, I wouldn't recommend it."
"in the meantime I use this adenosine receptor. um agonist or antagonist, the KW. So, uh energy levels are good and uh I just got to make sure that it doesn't interfere with wound healing."
Show 1 more cited mention on background and overview →
"the KW is strong, so that's the adenosine receptor blocker and that's similar to caffeine with a very long half-life. I take 1 mg."
KW-6356 Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve / Steve | Prevent Insulin Resistance On High-Dose GH, Mirabegron Vs. Clen Vs.... | 01:30:13 | Vigorous Steve reported using 1-1.5 mg first thing in the morning as an alternative to multiple coffees. He described it as a long-half-life adenosine receptor agonist and reported finding it useful for managing high-dose GH lethargy, but noted it did not help with ATX lethargy. | anecdotal |
| Vigorous Steve | Trenbolone’s Minimum Dose, Generic GH Gone, SS-31 Effective Dose,... | 01:27:01 | Steve reported using 1-1.25 mg in the morning as an alternative to multi-dose coffee; he described it as providing stable energy throughout the day, which he attributed to adenosine receptor activity (anecdotal, not clinically verified). | anecdotal |
| Vigorous Steve | Low-Dose MENT Year-Round, Melt Love Handle Fat, Injectable YK-11,... | 01:17:50 | Steve reported 1 mg preferred, 1.5 mg too much; with an 18-hour half-life, his reported protocol was twice weekly dosing (Wed/Sat) post leg day | anecdotal |
| Vigorous Steve | Oral Vs Injectable SLU-PP-332, Ideal GH To Test Ratio, High... | 00:34:18 | 1-1.25 mg/day (5 mg/mL liquid dropper, take 0.25 ml = 1.25 mg). Adenosine receptor blocker, long half-life like caffeine | anecdotal |
Where to Buy KW-6356 in 2026
No tracked vendor recommendations for KW-6356 yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss KW-6356. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“It's an adenosine blocker similar to caffeine but it's a little bit more selective and it's longlasting. So if you take that in the morning instead of having to dose coffee multiple times per day,...”
See 3 more expert mentions →
-
“The problem with KW-6356 is that it is 18-hour half-life. So for the people who are kind of sensitive to stimulants and don't really work hard, train hard, poor sleep hygiene, I wouldn't recommend it.”
-
“in the meantime I use this adenosine receptor. um agonist or antagonist, the KW. So, uh energy levels are good and uh I just got to make sure that it doesn't interfere with wound healing.”
-
“the KW is strong, so that's the adenosine receptor blocker and that's similar to caffeine with a very long half-life. I take 1 mg.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about KW-6356. Each line links to the original source.
- "Overall, 168 patients were randomized and treated (KW-6356 3 mg/day n = 55; 6 mg/day n = 58, placebo n = 55); Week 12 completion rates were >90% per group." · Maeda T et al, 2023 PubMed
- "LS mean [95% CI] changes from baseline to Week 12 in MDS-UPDRS Part III total scores were -5.37 [-7.25, -3.48] for 3 mg/day, -4.76 [-6.55, -2.96] for 6 mg/day and -3.14 [-4.97, -1.30] for placebo." · Maeda T et al, 2023 PubMed
KW-6356 Research Findings in Numbers
Quantitative results quoted verbatim from the indexed peer-reviewed studies and attributed clinical protocols below.
- 1-1.25 mg via 0.25 ml of 5 mg/ml dropper Vigorous Steve
- 1-1.25 mg from a 5 mg/ml dropper (0.25 ml) Steve
- 1 mg to 1.25 mg as adenosine receptor blocker Steve
- Steve reported using 1 mg to 1.25 mg via dropper (0.25 ml of 5 mg/ml) Steve
- 1.5 mg too much for some Steve
- 1 mg KW-6356 (1.5 mg felt like too much) Vigorous Steve
- 1-1.25 mg in morning upon waking Steve
- 1-1.25 mg/day (5 mg/mL liquid dropper, take 0.25 ml = 1.25 mg). Vigorous Steve
- 1-1.25 mg upon waking Vigorous Steve
- Vigorous Steve reported preferring 1 mg, noting 1.5 mg may be too much, dosed twice weekly (Wednesday/Saturday after leg day). Vigorous Steve
- Steve reported 1 mg preferred, 1.5 mg too much Steve
Research and Studies
6 PubMed-indexed papers reference KW-6356. Top 6 shown.
Legal Status
KW-6356 is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-16.
Frequently Asked Questions
Is KW-6356 FDA-approved?
KW-6356 is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for KW-6356?
This page aggregates 4 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on KW-6356?
6 PubMed-indexed paper(s) reference KW-6356 in our current research feed. See the Research and Studies section above for citations.